A5085245138- Chronic Obstructive Pulmonary Disease (COPD) Research
- Respiratory and Cough-Related Research
- Asthma and respiratory diseases
- Respiratory Support and Mechanisms
- Pediatric health and respiratory diseases
- Ophthalmology and Visual Impairment Studies
- Retinal Development and Disorders
- Inhalation and Respiratory Drug Delivery
- Health Systems, Economic Evaluations, Quality of Life
- Retinopathy of Prematurity Studies
- Intraocular Surgery and Lenses
- Childhood Cancer Survivors' Quality of Life
- Corneal surgery and disorders
- Retinal Diseases and Treatments
- Delphi Technique in Research
- Heart Failure Treatment and Management
- Adolescent and Pediatric Healthcare
- Analytical Methods in Pharmaceuticals
- Adrenal Hormones and Disorders
- Nursing Diagnosis and Documentation
- Cystic Fibrosis Research Advances
- Retinal and Optic Conditions
- Health Literacy and Information Accessibility
- Older Adults Driving Studies
- Health, Environment, Cognitive Aging
Novartis (Switzerland)
2014-2023
Novartis (United Kingdom)
2018
Université Paris Cité
2016
Lung Institute
2016
Clinical Research Institute
2015
University of North Carolina at Chapel Hill
2015
Novartis (India)
2015
University of Bari Aldo Moro
1988
IRCCS Istituto Auxologico Italiano
1985
Most guidelines recommend either a long-acting beta-agonist (LABA) plus an inhaled glucocorticoid or muscarinic antagonist (LAMA) as the first-choice treatment for patients with chronic obstructive pulmonary disease (COPD) who have high risk of exacerbations. The role LABA-LAMA regimen in these is unclear.We conducted 52-week, randomized, double-blind, double-dummy, noninferiority trial. Patients had COPD history at least one exacerbation during previous year were randomly assigned to...
There are no studies on withdrawal of inhaled corticosteroids in patients long-term triple therapy the absence frequent exacerbations.To evaluate efficacy and safety direct de-escalation from to indacaterol/glycopyrronium nonfrequently exacerbating with chronic obstructive pulmonary disease (COPD).This 26-week, randomized, double-blind, triple-dummy study assessed change (110/50 μg once daily) or continuation (tiotropium [18 μg] daily plus combination salmeterol/fluticasone propionate...
Background: The current Global initiative for chronic Obstructive Lung Disease (GOLD) treatment strategy recommends the use of one or more bronchodilators according to patient's airflow limitation, their history exacerbations, and symptoms. LANTERN study evaluated effect long-acting β 2 -agonist (LABA)/long-acting muscarinic antagonist (LAMA) dual bronchodilator, QVA149 (indacaterol/glycopyrronium), as compared with LABA/inhaled corticosteroid, salmeterol/fluticasone (SFC), in patients...
Rationale: Post hoc analyses suggest that blood eosinophils have potential as a predictive biomarker of inhaled corticosteroid efficacy in the management chronic obstructive pulmonary disease (COPD).Objectives: We prospectively investigated value predictor responsiveness to an corticosteroid/long-acting β2-agonist combination versus long-acting β2-agonist/long-acting muscarinic antagonist for exacerbation prevention.Methods: conducted prespecified data from FLAME (Effect Indacaterol...
Rationale: Current Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy recommends the combination of two long-acting bronchodilators different pharmacologic classes management chronic obstructive pulmonary disease (COPD) if symptoms are not adequately controlled by a single bronchodilator.Objectives: The FLIGHT1 and FLIGHT2 studies evaluated efficacy safety QVA149 (indacaterol/glycopyrrolate), fixed-dose β2-agonist (indacaterol) muscarinic antagonist (glycopyrrolate),...
Background: The FLAME study demonstrated that indacaterol/glycopyrronium (IND/GLY), the fixed-dose combination of a long-acting β 2 -agonist (LABA, IND) and muscarinic antagonist (LAMA, GLY), was superior to salmeterol/fluticasone (SFC) in preventing exacerbations COPD patients with high risk exacerbations. In this study, we report prespecified analysis efficacy safety IND/GLY versus SFC Asian from study. Patients methods: centers moderate-to-very severe ≥1 exacerbation previous year...
Chronic obstructive pulmonary disease (COPD) is a progressive and composite endpoint could be an indicator of treatment effect on worsening. This post-hoc analysis assessed whether indacaterol/glycopyrronium (IND/GLY) 110/50 μg once daily reduced the risk clinically important deterioration (CID) versus salmeterol/fluticasone (SFC) 50/500 twice in moderate-to-very severe COPD patients from FLAME study. CID was defined as ≥100 mL decrease forced expiratory volume 1 s (FEV1) or ≥ 4-unit...
Section:ChooseTop of pageAbstract <<The Many Faces HCRU-de...Regulatory GuidanceSymptom Diary CardsElectronic Symptom ...The Exacerbations and Sym...Exacerbations Chronic ...Health Status MeasuresChronic Respiratory Disea...Interpreting HCRU PRO...Future DevelopmentsConclusionsReferencesCITING ARTICLES
Abstract Rationale The long-acting β 2 -agonist/long-acting muscarinic antagonist combination indacaterol/glycopyrronium (IND/GLY) elicits bronchodilation, improves symptoms, and reduces exacerbations in COPD. Magnetic resonance imaging (MRI) of the lung with hyperpolarized gas gadolinium contrast enhancement enables assessment whole functional responses to IND/GLY. Objectives primary objective was effect IND/GLY on global ventilated volume (%VV) versus placebo Lung function, regional...
Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD moderate-to-severe airflow limitation: the GEM1 study Craig LaForce,1 Gregory Feldman,2 Selwyn Spangenthal,3 Joerg H Eckert,4 Michelle Henley,5 Francesco Patalano,4 Peter D'Andrea5 1North Carolina Clinical Research, Raleigh, NC, USA; 2South Pharmaceutical Spartanburg, SC, 3American Health Charlotte, 4Novartis Pharma AG, Basel, Switzerland; 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA...
The association between clinically relevant changes in patient-reported outcomes (PROs) and forced expiratory volume 1 s (FEV
We illustrate our experience of gathering patient insights on the most patient-relevant symptoms in chronic obstructive pulmonary disease (COPD) via a structured and systematic approach towards 'patient-centric' drug development, leveraging recent advances digital technologies using online platforms. The four-step comprised following: literature search, social media listening (SML) study, bulletin board (OBB) exercise, design an preference study (PPS). initial studies (SML OBB) revealed...
To compare the insights obtained about experience of individuals with presbyopia (age-related impaired near vision) across three different sources qualitative data: a structured targeted literature review, social media listening (SML) and concept elicitation (CE) interviews healthcare professionals (HCPs). The number concepts identified, depth data, cost time implications, value patient generated were explored compared for each method.
Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis CRYSTAL study Timm Greulich,1 Konstantinos Kostikas,2 Mina Gaga,3 Maryam Aalamian-Mattheis,2 Nadine S Lossi,4 Francesco Patalano,2 Xavier Nunez,5 Veronica A Pagano,5 Robert Fogel,6 Claus F Vogelmeier,1,* Andreas Clemens2,7,* 1University Medical Center Giessen and Marburg, German for Lung Research (DZL), Germany;...